Immuneering Corporation

NasdaqGM IMRX

Immuneering Corporation Shareholders' Equity for the quarter ending September 30, 2024: USD 57.72 M

Immuneering Corporation Shareholders' Equity is USD 57.72 M for the quarter ending September 30, 2024, a -44.51% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Immuneering Corporation Shareholders' Equity for the quarter ending September 30, 2023 was USD 104.02 M, a -14.66% change year over year.
Immuneering Corporation Shareholders' Equity for the quarter ending September 30, 2022 was USD 121.89 M, a -23.00% change year over year.
Immuneering Corporation Shareholders' Equity for the quarter ending September 30, 2021 was USD 158.29 M.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqGM: IMRX

Immuneering Corporation

CEO	Dr. Benjamin J. Zeskind M.B.A., Ph.D.
IPO Date	July 30, 2021
Location	United States
Headquarters	245 Main Street
Employees	66
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Key trends

Past 5 years